161 related articles for article (PubMed ID: 34235560)
1. 24-Month Efficacy and Safety Results from Japanese Patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent.
Iida O; Fujihara M; Kawasaki D; Mori S; Yokoi H; Miyamoto A; Kichikawa K; Nakamura M; Ohki T; Diaz-Cartelle J; Müller-Hülsbeck S; Gray WA; Soga Y
Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1367-1374. PubMed ID: 34235560
[TBL] [Abstract][Full Text] [Related]
2. Japanese Patients Treated in the IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents.
Soga Y; Fujihara M; Iida O; Kawasaki D; Hirano K; Yokoi H; Miyamoto A; Kichikawa K; Nakamura M; Ohki T; Diaz-Cartelle J; Gray WA; Müller-Hülsbeck S
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):215-222. PubMed ID: 31690980
[TBL] [Abstract][Full Text] [Related]
3. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent.
Müller-Hülsbeck S; Benko A; Soga Y; Fujihara M; Iida O; Babaev A; O'Connor D; Zeller T; Dulas DD; Diaz-Cartelle J; Gray WA
Cardiovasc Intervent Radiol; 2021 Mar; 44(3):368-375. PubMed ID: 33225377
[TBL] [Abstract][Full Text] [Related]
4. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention.
Gray WA; Griffiths RI; Elroy PWM; Amorosi SL; McGovern AM; Jaff MR; Akehurst R; Müller-Hülsbeck S
J Med Econ; 2022; 25(1):880-887. PubMed ID: 35703041
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
Gouëffic Y; Torsello G; Zeller T; Esposito G; Vermassen F; Hausegger KA; Tepe G; Thieme M; Gschwandtner M; Kahlberg A; Schindewolf M; Sapoval M; Diaz-Cartelle J; Stavroulakis K;
Circulation; 2022 Nov; 146(21):1564-1576. PubMed ID: 36254728
[TBL] [Abstract][Full Text] [Related]
7. Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value.
Gray WA; Soga Y; Fujihara M; Iida O; Babaev A; Kawasaki D; Zeller T; O'Connor D; Jaff MR; Chavez AM; Müller-Hülsbeck S
J Comp Eff Res; 2024 Jun; 13(6):e240025. PubMed ID: 38606556
[No Abstract] [Full Text] [Related]
8. Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent.
Golzar J; Soga Y; Babaev A; Iida O; Kawasaki D; Bachinsky W; Park J; Prem JT; Vermassen F; Diaz-Cartelle J; Müller-Hülsbeck S; Gray WA
J Endovasc Ther; 2020 Apr; 27(2):296-303. PubMed ID: 31989856
[No Abstract] [Full Text] [Related]
9. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
[No Abstract] [Full Text] [Related]
10. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
Dake MD; Fanelli F; Lottes AE; O'Leary EE; Reichert H; Jiang X; Fu W; Iida O; Zen K; Schermerhorn M; Zeller T; Ansel GM
Cardiovasc Intervent Radiol; 2021 Feb; 44(2):196-206. PubMed ID: 33025243
[TBL] [Abstract][Full Text] [Related]
11. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
Sugimoto M; Komori K; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
J Endovasc Ther; 2021 Apr; 28(2):229-235. PubMed ID: 33084502
[TBL] [Abstract][Full Text] [Related]
13. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
[TBL] [Abstract][Full Text] [Related]
14. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
[TBL] [Abstract][Full Text] [Related]
16. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
[TBL] [Abstract][Full Text] [Related]
17. One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.
Soga Y; Fujihara M; Tomoi Y; Iida O; Ishihara T; Kawasaki D; Ando K
J Atheroscler Thromb; 2020 Feb; 27(2):164-171. PubMed ID: 31257301
[TBL] [Abstract][Full Text] [Related]
18. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
[TBL] [Abstract][Full Text] [Related]
19. One Year Outcomes of Zilver PTX Versus Eluvia for Femoropopliteal Disease in Real-World Practice: REALDES Study.
Shibata T; Iba Y; Shingaki M; Yamashita O; Tsubakimoto Y; Kimura F; Hatada A; Kasashima F; Ueno K; Nakanishi K; Morishita K; Nakajima T; Nakazawa J; Ohkawa A; Hosaka I; Arihara A; Tsushima S; Kawaharada N
J Endovasc Ther; 2023 Jun; ():15266028231179861. PubMed ID: 37291881
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
Dake MD; Ansel GM; Bosiers M; Holden A; Iida O; Jaff MR; Lottes AE; O'Leary EE; Saunders AT; Schermerhorn M; Yokoi H; Zeller T
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):8-19. PubMed ID: 31502026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
